Literature DB >> 26300465

Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis.

Xi-Ping Zhou1, Bing Liu1, Qun Xu2, Yang Yang2, Chun-Xia He1, Ya-Gang Zuo1, Yue-Hua Liu1.   

Abstract

Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease, and different immunoglobulin (Ig)G autoantibody subclasses may play different roles in the pathogenesis of BP. This study aims to evaluate the relationship between specific IgG subclasses and BP. Enzyme-linked immunoassays (ELISA) were developed to test the IgG subclasses targeting the non-collagenous 16A (NC16A) domain of BP180. A statistical analysis was carried out to assess the relationship of BP and IgG subclasses as well as other factors. The correlation coefficients between the ELISA scores for four IgG subclasses and disease severity scores were 0.586 for IgG, 0.441 for IgG1, 0.594 for IgG2, 0.345 for IgG3, and 0.448 for IgG4 before treatment. After treatment, the correlation coefficient was 0.376 for IgG, 0.522 for IgG1, 0.314 for IgG2, 0.582 for IgG3 and 0.503 for IgG4. Spearman's rank correlation coefficient was 0.801 for IgG1, 0.66 for IgG2, 0.575 for IgG3 and 0.463 for IgG4 between the ELISA scores of IgG subclasses and the disease severity score variation. The ELISA scores of IgG subclasses in patients with mucosal involvement were higher than those without. Survival analysis showed that sex, IgG1 and IgG4 were the independent predictors for BP. In conclusion, the serum levels of IgG1 and IgG4 targeting BP180NC16A were paralleled with disease severity in BP patients. IgG1 and IgG4 and sex were the independent prognostic factors for an early prognosis of BP.
© 2015 Japanese Dermatological Association.

Entities:  

Keywords:  BP180; autoantibody; bullous; immunoglobulin G; pemphigoid; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26300465     DOI: 10.1111/1346-8138.13051

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  7 in total

1.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

2.  Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.

Authors:  S Emtenani; H Yuan; C Lin; M Pan; J E Hundt; E Schmidt; L Komorowski; J R Stanley; C M Hammers
Journal:  Br J Dermatol       Date:  2019-01-01       Impact factor: 9.302

Review 3.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 4.  Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.

Authors:  Connor Cole; Keshavamurthy Vinay; Luca Borradori; Kyle T Amber
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

Review 5.  The relevance of complement in pemphigoid diseases: A critical appraisal.

Authors:  Cristian Papara; Christian M Karsten; Hideyuki Ujiie; Enno Schmidt; Leon F Schmidt-Jiménez; Adrian Baican; Patricia C Freire; Kentaro Izumi; Katja Bieber; Matthias Peipp; Admar Verschoor; Ralf J Ludwig; Jörg Köhl; Detlef Zillikens; Christoph M Hammers
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

Review 6.  Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review.

Authors:  Xinyi Chen; Wenlin Zhao; Hongzhong Jin; Li Li
Journal:  Front Med (Lausanne)       Date:  2021-05-20

Review 7.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.